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Abstract
Most prostate cancers (PC) are currently found on the basis of
an elevated PSA, although this biomarker has only moderate
accuracy. Histological confirmation is traditionally obtained
by random transrectal ultrasound guided biopsy, but this ap-
proach may underestimate PC. It is generally accepted that a
clinically significant PC requires treatment, but in case of an
non-significant PC, deferment of treatment and inclusion in an
active surveillance program is a valid option. The implemen-
tation of multiparametric magnetic resonance imaging
(mpMRI) into a screening program may reduce the risk of
overdetection of non-significant PC and improve the early
detection of clinically significant PC. A mpMRI consists of
T2-weighted images supplemented with diffusion-weighted
imaging, dynamic contrast enhanced imaging, and/or
magnetic resonance spectroscopic imaging and is preferably
performed and reported according to the uniform quality stan-
dards of the Prostate Imaging Reporting and Data System
(PIRADS). International guidelines currently recommend
mpMRI in patients with persistently rising PSA and previous
negative biopsies, but mpMRI may also be used before first
biopsy to improve the biopsy yield by targeting suspicious
lesions or to assist in the selection of low-risk patients in
whom consideration could be given for surveillance.
Teaching Points
• MpMRI may be used to detect or exclude significant prostate
cancer.
• MpMRI can guide targeted rebiopsy in patients with previ-
ous negative biopsies.
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• In patients with negative mpMRI consideration could be
given for surveillance.
•MpMRI may add valuable information for the optimal treat-
ment selection.
Keywords Prostate . Prostatic neoplasms .Magnetic
resonance imaging .Magnetic resonance spectroscopy .
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Introduction
Most prostate cancers (PC) are currently found on the basis of
an elevated serum prostate specific antigen (PSA) level. At
present, PSA is the best standard biomarker used for early
detection of PC [1–4], although it has only moderate sensitiv-
ity (PC may still be present at low levels of PSA) and speci-
ficity (benign prostatic hyperplasia or prostatitis may cause
false positive results) [1, 2, 5, 6]. In patients with elevated
PSA, histological confirmation is needed and this is tradition-
ally obtained using random transrectal ultrasound (TRUS)
guided prostate biopsy [7]. This approach, however, yields
false negative results in up to 40 % of cases and may show
underestimation of Gleason grade, especially in anteriorly lo-
cated tumours [8–10]. Treatment selection is based on prog-
nostic factors including serum PSA level, histological grading
(Gleason score), tumour size, clinical staging (TNM), and
patient’s life expectancy [1, 4, 5]. Population-based PC
screening with PSA is discouraged by international guide-
lines, because of potential overdiagnosis and subsequently
overtreatment of non-lethal disease [11, 12].
The implementation of multiparametric magnetic reso-
nance imaging (mpMRI) into a screening program cur-
rently seems to be the most promising technique to reduce
the risk of overdetection of non-significant PC and im-
prove the early detection of clinically significant PC
[13]. The role of mpMRI has evolved in the past decade.
The EAU, NCCN, and ESUR guidelines currently recom-
mend the use of mpMRI in patients with persistently ris-
ing PSA and previous negative biopsies in an attempt to
visualize the PC and consequently make targeted rebiopsy
possible [13–17]. New MRI sequences and scanning tech-
niques have boosted the diagnostic accuracy of mpMRI
and its potential to be used as an additional decision tool
before first biopsy to improve the biopsy yield or to assist
in the selection of men who might reasonably defer un-
necessary biopsy [5, 13, 18, 19].
In this paper we give an overview of the mpMRI technique,
its performance in PC detection, and in the assessment of
tumour aggressiveness and size. The role of mpMRI in early
detection of clinically significant PC is highlighted.
Clinical significance of a PC
It is generally accepted that a PC with a Gleason score of ≥4+
3 and/or non-organ confined disease is clinically significant
and requires treatment depending on patients’ life expectancy
[20, 21]. Substantial recent data suggest that a small PC with
pure Gleason 3+3 does not pose a significant threat to a man’s
life allowing deferment of treatment and inclusion in an active
surveillance program as a valid option [22, 23]. There is more
discussion among urologists about the clinical significance of
a large Gleason 3+3 PC or a Gleason 3+4 PC with limited
grade 4 (less than 10 %) [20, 22, 24]. Epstein et al. recently
proposed a new PC grading system based on the Gleason
scores with grade group 1 including all Gleason score 6, grade
group 2 including Gleason score 3+4, grade group 3 Gleason
score 4+3, grade group 4 Gleason score 8, and grade group 5
Gleason score 9–10 PC. This simplified grading system
avoids the logical yet incorrect assumption for patients with
a Gleason score 6 PC that their cancer is in the middle of a
scale of 2 to 10 (fromGleason score 1+1 to Gleason score 5+
5), potentially reducing anxiety and overtreatment for indolent
disease [25]. Further, this novel grading system highlights the
different prognosis of men with Gleason score 7, according to
the presence of a primary or a secondary pattern 4.
Multiparametric magnetic resonance imaging
A mpMRI consists of morphological T2-weighted images
(T2-WI) supplemented with functional imaging techniques
such as diffusion-weighted imaging (DWI), dynamic contrast
enhanced imaging (DCE), and/or magnetic resonance spectro-
scopic imaging (MRSI) [14]. This results in a combination of
anatomical, biological, and functional information.
On T2-WI the prostatic morphology is depicted with high
resolution. The transition zone (TZ) of the prostate consists of
nodular areas of stromal and glandular hyperplasia with vary-
ing signal intensity (SI), and is surrounded posteriorly and
laterally by the peripheral zone (PZ) that usually has a more
homogeneous high SI [26, 27]. PC can be identified on T2-WI
as an ill-defined low SI area, contrasting well with the normal
high background SI of the PZ, but often more difficult to
distinguish in the TZ [28, 29]. The reported sensitivities and
specificities for detection of PC with T2-WI range between
57 %-88 % and 28 %-94 %, respectively [18, 28, 30–41]. The
lower specificities may be explained by diseases with low SI
areas in the PZ mimicking PC. Nevertheless, T2-WI has been
assumed to be the dominant sequence for the identification of
PC in the TZ when interpreting imaging findings of a mpMRI
exam [42, 43].
DWI provides information about the amount of random
movement of water molecules in a tissue [44, 45]. In healthy
prostate glands the water molecules move relatively
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unhindered but in PC the motion is strongly inhibited.
This is depicted on DWI as a high SI area on high-b-
value images with a corresponding low apparent diffusion
coefficient (ADC) [44–47]. The reported sensitivities and
specificities of DWI for detection of PC range from 57-
93 % and 57-100 %, respectively [48, 49]. DWI has been
observed to be the best-performing single parameter for
detection of PC in the PZ deserving the strongest
weighting in a mpMRI exam [43, 50].
In DCE, the prostate is evaluated on serial T1-weighted
images after an intravenous bolus injection of contrast agent
[5, 51]. The shape of the dynamic enhancement curve depends
on vascular permeability in the examined tissue. Most PC are
associated with neoangiogenesis and increased vascular per-
meability resulting in pronounced contrast enhancement and a
curve showing high peak enhancement and early washout [5,
51]. Alternatively, several quantitative post-processing perfu-
sion MRI parameters have been developed, such as Ktrans, ve
and kep [45, 51, 52], but currently the localization of the en-
hancement (focal or diffuse and whether or not corresponding
to suspicious findings on T2 and/or DWI) as compared to the
adjacent normal prostatic tissue is considered more important
than the enhancement characteristics of the lesion itself. [53]
Accuracies of 70 to 90 % have been reported for DCE in
detection of PC [51, 52]. Mowatt et al. showed a pooled sen-
sitivity of 79 % (69 %-87 %) and a pooled specificity of 52 %
(14 %-88%) [41]. False positive enhancement in benign pros-
tatic hyperplastic nodules in the TZ or in prostatitis in the PZ
causes overlap in enhancement patterns between tumours and
benign conditions yielding lower specificity [54].
MRSI provides information about the relative concentra-
tions of cellular metabolites in the prostate such as citrate and
choline [5, 44, 55]. Citrate is synthesized, stored, and secreted
by healthy prostatic glandular tissue, and choline is an impor-
tant constituent in the cell membrane metabolism and its con-
centration increases in highly cellular areas such as in PC [55,
56]. The complimentary changes of both metabolites are used
to predict the presence or absence of PC. Diagnostic accura-
cies up to 70-90 % for detection of PC with MRSI have been
reported [44, 56–59]. Mowatt et al. showed a pooled sensitiv-
ity of 92 % (86 %-95 %) and pooled specificity of 76 %
(61 %-87 %) [41].
A mpMRI is preferably performed according to the
uniform quality standards of the European Society of
Urogenital Radiology (ESUR) guidelines [14]. For
reporting prostate mpMRI, many authors in the past have
used a subjective 5-point Likert score to communicate
the conclusion to the referring clinician, but in 2012
the ESUR introduced the Prostate Imaging Reporting
and Data System (PI-RADS) in analogy with the Breast
Imaging Reporting and Data System (BI-RADS) [14, 60,
61]. The PI-RADS reporting system entails assignment
of separate scores for each of the scanned mpMRI
sequences and provides explicit verbal descriptions on
how to generate them. Each exam is assigned with an
overall assessment score ranging from 1 (indicating that
clinically significant PC is highly unlikely to be present)
to 5 (indicating that clinically significant PC is highly
likely to be present) (Table 1). In 2015 a modified ver-
sion of PI-RADS was published, named PI-RADS ver-
sion 2 (PI-RADSv2), which was also adopted by the
American College of Radiology (ACR) [53]. The previ-
ous version of PI-RADS was from then on referred to as
PI-RADS version 1 (PI-RADSv1). In PI-RADSv1 the
overall assessment category score was based on a sub-
jective radiologist’s impression of the scanned sequences,
but in PI-RADSv2 two dominant modalities have been
defined, namely, DWI for the peripheral zone (PZ) and
T2-WI for the TZ, and well-defined instructions have
been provided on how to determine the overall assess-
ment score [43, 53, 62, 63].
Performance of mpMRI
Validation studies of mpMRI are accumulating and show
that this imaging technique provides high detection rates
of PC, but the location of the tumour in the prostate (PZ
or TZ), the volume, and histological characteristics such
as Gleason score highly influence its performance
[64–66]. The reported accuracy of mpMRI at detecting
PC varies with the definition of clinically significant PC,
and the mpMRI threshold that is used (i.e., whether PI-
RADS 3 is considered positive or negative) [67, 68]. With
mpMRI, sensitivities and specificities of 71-84 % and 33-
70 %, respectively, are reported for detection of PC of any
grade, and 80-90 % and 47-61 %, respectively, for detec-
tion of high-grade (HG) PC [28, 69–80]. A recently pub-
lished systematic review reported accuracies of 44-87 %,
sensitivities of 58-97 %, and specificities of 23-87 % for
detection of clinically significant PC using mpMRI, with
trends depending highly on the threshold used in the def-
inition of clinically significant disease [81]. A meta-
analysis of 14 studies evaluating PI-RADS reported a
pooled sensitivity of 78 % (95 % CI 70 %-84 %) and
pooled specificity of 79 % (95 % CI 68 %-86 %) for
detection of PC with mpMRI [82]. Abd-Alazeez et al.
reported that, when a PI-RADS overall assessment score
of 3 was used as threshold for a positive mpMRI, 100 %
sensitivity and 100 % NPV was achieved for detection of
Gleason 4 + 3 PC, at the expense of 19 % specificity due
to many false positives. When a PI-RADS overall assess-
ment score of 4 was used as a threshold for the detection
of Gleason 4 + 3 PC, specificity increased to 61 % (indi-
cating less false positives), with still having a sensitivity
of 92 % and a NPV of 99 % [68].
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Assessing tumour aggressiveness and size
with mpMRI
The histological Gleason score is a critical predictor of PC
aggressiveness, and correlations have been reported between
PC Gleason score and T2, DWI, and MRSI suggesting that
mpMRI may be able to non-invasively assess PC aggressive-
ness [5, 55, 57, 64–66, 83, 84]. OnDWI, lower ADC values are
strongly correlated with higher Gleason scores [44–46, 85–89].
On T2-WI, lower SI of a PC relative to muscle seems to be
associated with higher Gleason scores [90] and on MRSI the
relative concentrations of citrate and choline tend to correlate
with Gleason scores [57, 59, 91]. Higher grade PC are histo-
logically associated with more pronounced destruction of the
normal ductular system, more solid areas of tumour cells and
less fluid content as compared to lower grade PC, and, conse-
quently, show a higher detectability on mpMRI [64–66, 92].
On mpMRI, tumour size can be measured on high-
resolution axial, sagittal, and coronal T2-WI planes.
Assessment of size is easier when a lesion is sharply
demarcated than when it is ill-defined, but size estimates
show considerable inaccuracy with a little more overes-
timation than underestimation [72]. Very small tumours
<1 mm diameter are below the detection limit of
mpMRI, but a PC of 1 cm diameter (0.5 ml) is well
within the 3 or 4 mm spatial resolution of T2-WI
[64–66, 92, 93]. PC volume thus influences its detect-
ability on mpMRI with larger tumours being detected
more easily than smaller ones. While the prognostic val-
ue of tumour volume is questionable because the largest
foci may not necessarily represent the biologically most
significant tumours, small PC foci are often regarded as
clinically insignificant. Historically, a tumour volume of
less than 0.5 ml has been proposed as the threshold for
clinical significance [24, 94]. Recent studies estimate that
after accounting for tumour stage (maximum pT2) and
tumour grade (maximum Gleason score 6), a volume
threshold at 1.3 ml or even 2.5 ml may be applied [22,
24]. Moreover, most PC are multifocal, and controversy
exists about whether the total tumour volume in the pros-
tate should be taken into account, or only the volume of
the largest dominant (index) lesion [7, 24, 95–97].
PC detection rates on mpMRI, thus,depend highly on the
Gleason grade and size of the tumour, ranging from 21-29 %
for <0.5 ml tumours with Gleason 6 to 100 % for tumours
>2 ml with Gleason ≥8 [64]. MpMRI detects both higher
grade and larger PC more accurately suggesting that it may
perform particularly well for the detection of clinically signif-
icant disease.
Clinical role of mpMRI in early detection of PC
Until a few years ago, mpMRI of the prostate was main-
ly used for staging purposes after histological confirma-
tion of PC, but in recent years a re-evaluation of its
position is going on. The ability of mpMRI to selectively
detect higher grade and larger volume tumours may help
to discriminate between significant cancer from indolent
cancer, which is useful in the initial assessment of men
considering active surveillance [98], or it may exclude
significant cancer before biopsy, which might lead to a
refined diagnostic pathway. The information obtained
with mpMRI is potentially useful as an additional tool
in screening protocols for the assessment of patients with
elevated PSA, next to clinical risk stratification variables
such as digital rectal examination, patient’s age, ethnici-
ty, comorbidity, and family history. MpMRI may have
value in men with elevated PSA to help identify areas
in the prostate with high probability of being cancerous
to improve the biopsy yield, and it may even serve as a
triage test to determine which patient should undergo
prostate biopsy or in whom a biopsy may be deferred
[96]. The benefits of incorporating mpMRI into the di-
agnostic algorithm may outweigh its costs by preventing
unnecessary biopsies and reduce overtreatment when
mpMRI is negative, and by improving the characteriza-
tion of PC using (only) targeted biopsy to a suspicious
lesion when mpMRI is positive [67, 72, 96, 99–104].
Moreover, when mpMRI is performed before biopsy,
hemorrhagic post-biopsy artefacts [105] are avoided,
and, in case of a positive diagnosis of PC, the imaging
is immediately available for staging [68, 96]. The current
PC guidelines do not generally include mpMRI before
initial biopsy, but the arguments for scanning before bi-
opsy become stronger. The systematic review of Moore
et al. [106] showed that with pre-biopsy mpMRI and
targeted MRI-guided biopsy an equal number of clinical-
ly significant PC was detected (in 43 % of the presenting
population) as compared with standard random TRUS
Table 1 The PIRADS overall
assessment categories PIRADS 1 Clinically significant prostate cancer is highly unlikely to be present
PIRADS 2 Clinically significant prostate cancer is unlikely to be present
PIRADS 3 Clinically significant prostate cancer is equivocal
PIRADS 4 Clinically significant prostate cancer is likely to be present
PIRADS 5 Clinically significant prostate cancer is highly likely to be present
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biopsy, but a third fewer men were biopsied overall, a
greater proportion of men with clinically significant PC
was biopsied, and 10 % fewer men were attributed a
diagnosis of clinically insignificant PC. In the more re-
cent systematic review of Schoots et al. [107] MRI-
targeted biopsy (and omitting the biopsy when mpMRI
is negative) showed similar overall PC detection rates
(sensitivity of 0.81 vs 0.85), higher detection rates of
clinically significant PC (sensitivity of 0.91 vs 0.84),
and lower (unwanted) detection rates of insignificant
PC (sensitivity of 0.44 vs 0.83) as compared to random
TRUS-guided biopsy. Subgroup analysis revealed espe-
cially an improvement in PC detection in men with pre-
vious negative biopsy than in biopsy-naïve men (relative
sensitivity of 1.54 vs 1.10 for clinically significant PC
and 1.62 vs 0.97 for any PC) [107]. Tonttila et al. [108]
however recently performed a randomized prospective
blinded controlled trial and concluded that adding
mpMRI before biopsy did not improve PC detection
rates as compared to TRUS biopsy alone in patients with
elevated PSA. They reported that adding mpMRI elevat-
ed the detection rate from 57 % to 64 % for any PC and
from 45 % to 55 % for clinically significant PC, but both
differences were not statistically significant. This study
was, however, performed in a hospital-based practice set-
ting instead of a centre of excellence for prostate
mpMRI, which was reflected in mpMRI that were not
scanned or reported according to the PI-RADS standards
and limited experience of the urologists who performed
targeted biopsies using a cognitive approach, which may
all be considered major limitations that will have nega-
tively influenced the results [108].
Fig. 1 67-year-old man with
persistently elevating PSA up to
6 μg/l. On this mpMRI a very
suspicious lesion is detected in the
apex of the prostate at the left side
(white star). Morphologically it is
demonstrated as an area of low SI
with irregular margins on T2-WI
(a), low ADC value (b) with high
SI on the high-b-value image (c)
of the DWI, strong contrast
enhancement (d) with early and
high peak enhancement with
wash-out on the DCE curve (e).
On MRSI the citrate peaks are
reduced and the choline peaks
elevated. The overall assessment
score of this exam was PI-RADS
5. A targeted TRUS-biopsy with
knowledge of the mpMRI
findings (i.e., a MR-guided
biopsy with cognitive fusion)
confirmed a Gleason 4 + 5 PC in
the apex at the left side
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Targeted biopsy when mpMRI is suspicious
An accurate prostate biopsy is an important component in the
decision-making and treatment selection. A suspicious
mpMRI (PI-RADS overall assessment score 4 and 5) enables
image-guided targeted sampling at the suspicious areas to
overcome the limitations of the traditional blind systematic
prostate biopsy. MR-guided biopsies are becoming more and
more available, but there is currently no consensus on the
optimal technique. [17] In-bore MR-guided biopsy is accu-
rate, but requires considerable technical requirements, which
are lacking at most centres, and has significant cost and logis-
tic issues [17, 109]. As an alternative, suspicious lesions on
mpMRI may be targeted with TRUS biopsy. Cognitive regis-
tration (Fig. 1) requires the TRUS operator to mentally inte-
grate mpMRI findings with TRUS to target the lesion, which
works well for large anterior tumours, but is not as accurate as
an in-bore MR-guided biopsy in case of small lesions [108,
109]. Difficulties of merging mpMRI with TRUS may be
overcome with the newly developed MRI-TRUS fusion soft-
ware, but this also has limitations including mainly errors in
fusion due to spatial deformation of the prostate at TRUS
compared to MRI, and it is expensive and only available in
few specialized centres [109]. Suspicious lesions detected on
mpMRI may not be perfectly matched with TRUS-guided
biopsy, and this must be taken into account when faced with
a negative histopathological result [109]. MpMRI-guided bi-
opsy has a significantly higher PC detection rate and positive
core rate as compared to standard random TRUS-guided bi-
opsy or extended systematic biopsies, especially in patients
with previous negative biopsy [89, 106, 107, 110–114].
MpMRI is often able to detect the most aggressive PC focus,
but synchronous non-index tumour detection may be poor.
Therefore, it remains to be clarified whether it is safe to ex-
clusively biopsy the target lesion while abandoning additional
routine systematic biopsies or whether the target lesion should
only be biopsied at a higher sampling density as compared to
the rest of the tissue [97, 114].
Fig. 2 65-year-old man with
PSA of 3.2 μg/l. On T2-WI (a)
the PZ shows normal high SI. On
DWI, the ADC values in the PZ
are high (b) and the SI on the b-
1000 images is low (c). On DCE
the PZ shows no suspicious
contrast enhancement (d) and the
DCE curves show a linear pattern
(e). On MRSI (f) the spectra show
normal high citrate peaks and low
choline concentrations. The
overall conclusion of this mpMRI
exam was PI-RADS1. On the
basis of this mpMRI, a clinically
significant PC could be excluded
with high certainty. A biopsy may
reasonably be deferred, or if a
biopsy shows low grade PC in a
few cores, this patient is a good
candidate for active surveillance
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Defer biopsy when mpMRI is negative
In men with normal findings on mpMRI (PI-RADS overall
assessment score 1 or 2), the risk of a clinically significant PC
is very low. Negative predictive values (NPV) of 63-91 % are
reported for PC of any grade, and 92-100 % for clinically
significant PC (depending on the definition of clinically sig-
nificant disease used) in low risk men (PSA <10, DRE nor-
mal, no family history) [13, 28, 59, 69–75, 81, 101, 103].
Since the growth and stage progression of PC tend to be slow,
consideration could, therefore, reasonably be given to defer-
ring or even omitting a biopsy in these patients, as long as
there is continued monitoring with repetitive PSA sampling,
DRE, and/or mpMRI [13, 22, 99, 102, 103, 115] (Fig. 2).
MpMRI is negative in men with elevated PSA in 18-33 %,
indicating the potential number of patients in whom a biopsy
could be avoided [13, 67, 68, 99, 103, 115, 116]. Postponing a
biopsy may however hold a risk of missing or delaying a
diagnosis of PC, although the majority of the missed PC
on mpMRI seem to be low grade and organ-confined
[116]. The frequency of missed clinically significant PC
on mpMRI has been reported to be 9-13 % in a low risk
group (PSA< 10 and DRE normal) but 47-51 % in a
high risk group (PSA>10 and/or DRE abnormal) [103,
116], thus, in the high risk group the role of pre-biopsy
mpMRI might be limited. Missing clinically insignificant
PC may be regarded as an advantage rather than a draw-
back, given the harmful effects of overtreatment of indo-
lent disease. If it is anyhow detected, unnecessary treat-
ment should be avoided, which is actually the general
basis concept of active surveillance [22]. A useful way
to prevent identification of insignificant disease and
overtreatment for early PC might be for it not to be
diagnosed histopathologically, therefore surveillance
without biopsy, but repetitive mpMRI instead may be
an option, and it is likely that patients would prefer a
mpMRI rather than a biopsy [103].
The indeterminate mpMRI
The findings on mpMRI may be doubtful, e.g., in case of
heterogeneous low SI in the PZ on T2-WI, which may repre-
sent prostatitis but may hide or mimic PC, or in case of a small
lesion in the TZ, with a background of benign prostatic hyper-
plasia. In the PI-RADS system these findings are assigned an
overall assessment score 3, and in most publications this has
been considered as a positive signal to biopsy, although this
decision should not depend on the images alone. The clinician
should take into account a balance of factors such as PSA
level, age, comorbidity, competing mortality risk assessment,
and psychological factors [68].When the other clinical param-
eters are suggestive of significant PC, a patient with elevated
PSA and indeterminate mpMRI should have a biopsy, but if
the risk of a significant PC is estimated to be rather low, the
patient may benefit from follow-up PSA and/or repeat
mpMRI in 6 to 12 months [71].
Conclusion
MpMRI may be used as an additional parameter next to PSA
in the early detection of clinically significant PC. The accura-
cy of mpMRI for detecting clinically significant PC varies
with the definition of clinically significant disease and the
mpMRI threshold that is used. Pre-biopsy mpMRI improves
the accuracy of a prostate biopsy by targeting suspicious le-
sions. In low-risk patients with elevated PSA but a negative
mpMRI, consideration could be given to surveillance rather
than immediate biopsy.
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